Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy

Digestive Surgery

Volumn 20, Issue 6, 2003, Pages 500-505

  Shimada, S ^a   Inoue, K ^a   Kuramoto, M ^b   Suzuki, S ^b   Yamamoto, K ^a   Ogawa, M ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Yatsushiro Health Insurance General Hospital   (Japan)

Author keywords

Cytokine; Gastrectomy; Gastric carcinoma; Rebamipide; Systemic inflammatory response syndrome

Indexed keywords

ALANINE; C REACTIVE PROTEIN; CYTOKINE; DRUG DERIVATIVE; ENZYME INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; QUINOLONE DERIVATIVE; REBAMIPIDE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; BLOOD LEVEL; BODY TEMPERATURE; CANCER PATIENT; CHEMOPROPHYLAXIS; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEVER; GASTRECTOMY; HUMAN; LAPAROSCOPIC SURGERY; LAPAROSCOPY; LYMPH NODE DISSECTION; MALE; MEASUREMENT; METABOLISM; METHODOLOGY; PARAMETER; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROSPECTIVE STUDY; SEPSIS; STOMACH CANCER; STOMACH TUMOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

AGED; ALANINE; CHEMOPREVENTION; ENZYME INHIBITORS; FEMALE; FEVER; GASTRECTOMY; HUMANS; INTERLEUKIN-6; LAPAROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLONES; STOMACH NEOPLASMS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 0142165852     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073645     Document Type: Article

References (26)

1. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1991;215:356-362.
2. Hsu CD, Meaddough E, Aversa K, Hong SF, Lu LC, Jones DC, Copel JA: Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. Am J Obstet Gynecol 1998;179:1267-1270.
3. Lu C. Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS: Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1996;2:1417-1425.
4. Okamoto M, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997;72:149-154.
5. Sakamoto K, Arakawa H, Mita S, Ishiko T, Ikei S, Egami H, Hisano S, Ogawa M: Elevation of circulating interleukin-6 after surgery: Factors influencing the serum level. Cytokine 1994;6:181-186.
6. Bernard SL, Lorerg J: Age and immune response to a surgical stress. Arch Surg 1983;118:405-409.
7. Lennard TWJ, Shenton BK, Borztta A, Donnelly PK, Gerrie LM, Proud G, Taylor PMR: The influence of surgical operations on components of the human immune system. Br J Surg 1985;72:771-775.
8. Hattori T, Hamai Y, Takiyama W, Hirai T, Ikeda T: Enhancing effect of thoracotomy on tumor growth in rats with special reference to the duration and timing of the operation. Gann 1980;71:280-284.
9. Dinarello C: Interleukin-1 and pathogenesis of the acute-phase response. N Engl J Med 1984;311:1413-1418.
10. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Invest 1985;78:1349-354.
11. Wong GG, Clark SC: Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988;9:137-139.
12. Ikei S, Ogawa M, Beppu T, Ohara C, Sakamoto K, Sameshima H, Arakawa H, Yamaguchi Y, Yamanaka T, Kudo S: Changes in interleukin 6, interleukin 8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemoembolization therapy for hepatocellular carcinoma. Cytokine 1992;4: 581-584.
13. Adachi Y, Shiraishi N, Shiromizu A, Bandoh T, Aramaki M, Kitano S: Laparoscopy-assisted Billroth I gastrectomy compared with conventional open surgery. Arch Surg 2000;135:806-810.
14. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing, Dig Dis Sci 1998;43(suppl):5-13.
15. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 1998; 43(suppl):160-166.
16. Murakami K, Okajima K, Harada N, Isobe H, Okabe H: Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci 1998;43(suppl):139-142.
17. Shimada S, Yagi Y, Shiomori K, Honmyo U, Hayashi N, Matsuo A, Marutsuka T, Ogawa M: Characterization and proposal of the optimal therapeutic strategy for early gastric cancer. Surgery 2001;129:714-719.
18. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, English ed 1. Tokyo, Kanehara, 1999.
19. Mihara M, Haruma K, Kamada T, Kitadai Y, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Itoh H, Itoh K, Miyamoto M, Nishida T, Murakami S, Sanuki E, Ohmoto Y: The relationship between pathologic gastritis and mucosal interleukin-8 levels inducing the effect of rebamipide to mucosal interleukin-8 levels. Shokaki-ka 1997;24:681-688.
20. Nagano C, Azuma A, Ishiyama H, Sekiguchi K, Imagawa K, Kikuchi M: Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001;297:388-394.
21. Suzuki M, Miura S, Mori M, Kai A, Suzuki H, Fukumura D, Suematsu M, Tsuchiya M: Rebamipide, a novel antiulcer agent, attenuates Helicobacter pyloriinduced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994;35:1375-1378.
22. Naito Y, Yoshikawa T, Iinuma S, et al: Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittlelforschung 1996;46:698-700.
23. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK, Chi CW: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-1422.
24. Kabir S, Daar GA: Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995;95:207-212.
25. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Ka-jiyama G, Fidler IJ, Tahara E: Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998; 152:93-100.
26. Kishimoto T: The biology of interleukin-6. Blood 1989;74:1-10.